The French pharmaceutical and diagnostics company GuerbetS.A. has made a "substantial equity investment" in BoronBiologicals Inc. (BBI), Boron announced. The amount of theinvestment was not disclosed.
In May the two companies signed a research contract andlicensing agreement under which BBI of Raleigh, N.C., willdesign, synthesize and characterize new contrast agents.Guerbet is testing the agents and will receive exclusivemarketing and distribution rights to any compounds. Patentsresulting from the research will belong to both companies.
Guerbet also has supply and distribution agreements withAdvanced Magnetics Inc. covering two contrast agents, as wellas an agreement with American Biomed Inc. -- BrendaSandburg
(c) 1997 American Health Consultants. All rights reserved.